Search results for "Mabs"
Article
Best Practices for Selecting a Top-Quality Cell Line
Before scaling up to bioreactors, the productivity level for monoclonal antibodies (mAbs) should be 2–7 g/L (fed-batch culture in shake flask) or greater, observes Selexis CEO Igor Fisch. Once scaled …
Article
Biopharmaceutical Process Development: 2018 Lessons and 2019 Predictions
The biopharmaceutical industry continues to expand in new and exciting ways. What might be in store for 2019, and what important lessons should process developers take from 2018? Here, we look back …
Article
Unifying Continuous Biomanufacturing Operations
Benchtop systems, then, could be sufficient for the commercial production of some mAbs. Integrated continuous bioprocessing is already regularly being achieved in small research labs, according to Bon…
Article
Improvements in Protein A Chromatography
Process Development Forum speaks about Protein A chromatography with Glen Bolton, Scientific Director at Amgen. Bolton recently published a paper “Role of more than 40 years of improvement in Protei…
Article
A Risk-Based Genetic Characterization Strategy for Recombinant CHO Cell Lines Used for Clinical and Commercial Applications
Reichert, MAbs. 7 (1), pp. 1–8 (2015).
2. S.D. Wijesuriya, R.L. Cotter, and A.H. Horwitz, Protein Expr. Purif. 92 (1), pp. 14–20 (2013).
3. D. Guo et al., Biotechnol. Bioeng. 107 (1), pp. 163–17…
Article
Biopharma in 2015: A Year for Approvals and Innovations
mAbs show promise in treating Alzheimer’s, lymphoblastic leukemia, and are playing a role in helping to improve survival of patients with multiple mueloma.
Last year was also a year when novel biop…
Article
Modular Manufacturing Platforms for Biologics
By using modularization and the other aforementioned technologies such as continuous manufacturing, facilities to produce monoclonal antibodies (mAbs) can also be operational 12 months after project i…
Article
Continuous Manufacturing: A Changing Processing Paradigm
Case studies with mAbs have shown similar yield and purity compared with batch runs and could be associated with an increase in productivity, they note. Other advantages of continuous manufacturing in…
Article
Purification strategies for antibody-derived entities: bispecifics and fragments
Purification platforms used for many monoclonal antibodies (mAbs) need to be adopted for antibody variants to simplify protocols and improve purity and yield. The safety and efficiency requirement of …
Article
Selecting Chromatography Resins for Bispecific Antibody Purification
Their purification can be more challenging than traditional monoclonal antibodies (mAbs), however, due to the increased level of product-related impurities with high similarity to the desired bsAbs. A…